Refractive surgery grew by a surprising 14.7 percent during the quarter.
The market leaders were Novartis, Regeneron, and Bausch + Lomb.
Presenters applauded recent approvals but worried about a lean pipeline.
The IOL is the first FDA-approved lens that can be adjusted postoperatively to deliver the patient’s optimal prescription vision.
In one suit, Allergan alleges Imprimis uses ambiguity in federal law to skirt the agency’s rules for new drugs.
The segment is expected to total $4.9 billion in 2022.
Personalized medicine is on the horizon, one ophthalmologist told attendees.
Neil Bressler, MD, announced that the DRCR.net is expanding its mission from diabetic retinal disease to include AMD, inherited retinal disease, and other retinal diseases.
Presenters discussed instruments from Bausch + Lomb, Alcon, Katalyst, Vitreq, and other companies.
Eye care was a high priority for victims of hurricanes in 2017.
One surgeon reported that 93 percent of patients are satisfied with AT LARA lens.
Presentations included updates on the Iantech miLOOP, Mynosys Zepto, and CapsuLaser system.
Presenters reported results with LASIK, SMILE, surface ablation, corneal inlays, and custom ablation.
The implants are designed to restore the eye’s natural ability to focus at near and intermediate distances, without compromising distance vision.
Nineteen countries offered to host the regulatory agency.
The company also announced that it is ending its Eylea and nesvacumab combination program.
The drops employ the company’s water-free EyeSol delivery technology.
You are not currently logged in.
©2018 Market Scope
Lost your Password